Quanlin An

788 total citations · 1 hit paper
13 papers, 569 citations indexed

About

Quanlin An is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Quanlin An has authored 13 papers receiving a total of 569 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Quanlin An's work include Retinoids in leukemia and cellular processes (5 papers), Acute Myeloid Leukemia Research (2 papers) and Cancer Research and Treatments (2 papers). Quanlin An is often cited by papers focused on Retinoids in leukemia and cellular processes (5 papers), Acute Myeloid Leukemia Research (2 papers) and Cancer Research and Treatments (2 papers). Quanlin An collaborates with scholars based in China, Israel and United States. Quanlin An's co-authors include Xin Cao, Yehuda G. Assaraf, Xiaojing Du, Jiayun Hou, Xiangdong Wang, Biao Yu, Jing Wang, Pengfei Fang, Biwei Yang and Jinglin Xia and has published in prestigious journals such as Nature Communications, Journal of Medicinal Chemistry and Advanced Science.

In The Last Decade

Quanlin An

11 papers receiving 562 citations

Hit Papers

Carbohydrate-based drugs launched during 2000−2021 2022 2026 2023 2024 2022 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Carbohydrate-based drugs launched during 2000−2021
    2022 171 citations Xin Cao, Xiaojing Du et al. Acta Pharmaceutica Sinica B profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Quanlin An China 8 337 161 149 125 83 13 569
Seojeong Park South Korea 14 318 0.9× 178 1.1× 165 1.1× 54 0.4× 59 0.7× 33 578
Alessia Lopergolo Italy 15 365 1.1× 200 1.2× 115 0.8× 105 0.8× 65 0.8× 15 629
Christy W.S. Tong Hong Kong 6 287 0.9× 61 0.4× 162 1.1× 147 1.2× 92 1.1× 7 530
Tijana Stanković Serbia 18 386 1.1× 92 0.6× 183 1.2× 115 0.9× 64 0.8× 34 670
Michelle Helen Visagie South Africa 15 401 1.2× 110 0.7× 120 0.8× 185 1.5× 44 0.5× 33 698
Somsundaram Chettiar United States 12 283 0.8× 124 0.8× 161 1.1× 64 0.5× 61 0.7× 16 521
Silpa Narayanan United States 10 304 0.9× 63 0.4× 193 1.3× 67 0.5× 53 0.6× 18 518
Jean‐François Gaussin Belgium 7 343 1.0× 134 0.8× 114 0.8× 80 0.6× 49 0.6× 10 587
Xiaoying Lan China 15 461 1.4× 76 0.5× 227 1.5× 77 0.6× 47 0.6× 20 699
Soo‐Yeon Hwang South Korea 10 220 0.7× 57 0.4× 115 0.8× 66 0.5× 65 0.8× 22 374

Countries citing papers authored by Quanlin An

Since Specialization
Citations

This map shows the geographic impact of Quanlin An's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quanlin An with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quanlin An more than expected).

Fields of papers citing papers by Quanlin An

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Quanlin An. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quanlin An. The network helps show where Quanlin An may publish in the future.

Co-authorship network of co-authors of Quanlin An

This figure shows the co-authorship network connecting the top 25 collaborators of Quanlin An. A scholar is included among the top collaborators of Quanlin An based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Quanlin An. Quanlin An is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Zhao, Wenrui, Quanlin An, Lei Wang, et al.. (2025). Novel cancer stem cell-targeted retinoid ZSH-512 impedes colorectal cancer progress via KDM3A-mediated epigenetic reprogramming. The Innovation. 6(4). 100831–100831. 1 indexed citations
2.
An, Quanlin, Huaxin Song, Shujun Xiao, et al.. (2023). AcGlcAs: A Novel P53-Targeting Arsenical with Potent Cellular Uptake and Cancer Cell Selectivity. Journal of Medicinal Chemistry. 66(24). 16579–16596. 3 indexed citations
3.
Zhang, Yunjing, Jicheng Wu, Quanlin An, et al.. (2023). Renal tubule-targeted dexrazoxane suppresses ferroptosis in acute kidney injury by inhibiting ACMSD. Nano Research. 16(7). 9701–9714. 4 indexed citations
4.
Zheng, Linfeng, Xiangyang Qin, Jiao Wang, et al.. (2022). Discovery of MAO-B Inhibitor with Machine Learning, Topomer CoMFA, Molecular Docking and Multi-Spectroscopy Approaches. Biomolecules. 12(10). 1470–1470. 7 indexed citations
5.
Cao, Xin, Xiaojing Du, Quanlin An, et al.. (2022). Carbohydrate-based drugs launched during 2000−2021. Acta Pharmaceutica Sinica B. 12(10). 3783–3821. 171 indexed citations breakdown →
6.
Zhang, Yao, Qi Dong, Quanlin An, et al.. (2022). Synthetic Retinoid Kills Drug‐Resistant Cancer Stem Cells via Inducing RARγ‐Translocation‐Mediated Tension Reduction and Chromatin Decondensation. Advanced Science. 9(31). e2203173–e2203173. 10 indexed citations
7.
8.
Du, Xiaojing, Biwei Yang, Quanlin An, et al.. (2021). Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. The Innovation. 2(2). 100103–100103. 101 indexed citations
9.
Feng, Qi, Wenxing Qin, Yao Zhang, et al.. (2021). Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. Journal of Experimental & Clinical Cancer Research. 40(1). 17 indexed citations
10.
Song, Qian, Quanlin An, Bing Niu, et al.. (2019). Role of miR-221/222 in Tumor Development and the Underlying Mechanism. Journal of Oncology. 2019. 1–15. 62 indexed citations
11.
Cao, Xin, Jiayun Hou, Quanlin An, Yehuda G. Assaraf, & Xiangdong Wang. (2019). Towards the overcoming of anticancer drug resistance mediated by p53 mutations. Drug Resistance Updates. 49. 100671–100671. 136 indexed citations
12.
13.
Chen, Junwei, Xin Cao, Quanlin An, et al.. (2018). Inhibition of cancer stem cell like cells by a synthetic retinoid. Nature Communications. 9(1). 1406–1406. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Seojeong Park Breakdown of academic impact, for papers by Alessia Lopergolo Breakdown of academic impact, for papers by Christy W.S. Tong Breakdown of academic impact, for papers by Tijana Stanković Breakdown of academic impact, for papers by Michelle Helen Visagie Breakdown of academic impact, for papers by Somsundaram Chettiar Breakdown of academic impact, for papers by Silpa Narayanan Breakdown of academic impact, for papers by Jean‐François Gaussin Breakdown of academic impact, for papers by Xiaoying Lan Breakdown of academic impact, for papers by Soo‐Yeon Hwang
Rankless by CCL
2026